

Yu Zuo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/823779/yu-zuo-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

2,047

citations

11

h-index

28

g-index

28

ext. papers

2,862

ext. citations

6

avg, IF

5.38

L-index

#	Paper	IF	Citations
26	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	795
25	Neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2020 , 5,	9.9	575
24	Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	277
23	Neutrophil extracellular traps and thrombosis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 446-453	5.1	99
22	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021 , 11, 1580	4.9	81
21	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. <i>Journal of Leukocyte Biology</i> , 2021 , 109, 67-72	6.5	60
20	New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. <i>JCI Insight</i> , 2020 , 5,	9.9	28
19	Autoantibodies stabilize neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2021 , 6,	9.9	18
18	The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101661	5.3	18
17	Endothelial cell-activating antibodies in COVID-19 2021 ,		13
16	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10	1.7	12
15	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020 , 133, 929-940	2.9	11
14	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. <i>Viruses</i> , 2021 , 13,	6.2	10
13	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients 2020 ,		10
12	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018 , 20, 66	4.9	10
11	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. <i>JCI Insight</i> , 2021 , 6,	9.9	7
10	Autoantibodies stabilize neutrophil extracellular traps in COVID-19 2021 ,		5

9	Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 980-985	3.3	4
8	A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. <i>Lupus</i> , 2017 , 26, 606-615	2.6	4
7	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
6	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 215-227	5.3	2
5	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide 2021 ,		2
4	Myopathy in a 61-year-old Hispanic man. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	1
3	The role of cardiovascular disease risk assessed by ASCVD score in primary thrombosis prophylaxis strategy among antiphospholipid antibody carriers. <i>Lupus</i> , 2018 , 27, 2177-2178	2.6	1
2	Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers. <i>Lupus</i> , 2021 , 30, 828-832	2.6	0
1	Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.. <i>Pediatric Rheumatology</i> , 2022 , 20, 17	3.5	0